Online citations, reference lists, and bibliographies.
← Back to Search

Mitoxantrone Loaded Superparamagnetic Nanoparticles For Drug Targeting: A Versatile And Sensitive Method For Quantification Of Drug Enrichment In Rabbit Tissues Using HPLC-UV

R. Tietze, E. Schreiber, S. Lyer, C. Alexiou
Published 2010 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
In medicine, superparamagnetic nanoparticles bound to chemotherapeutics are currently investigated for their feasibility in local tumor therapy. After intraarterial application, these particles can be accumulated in the targeted area by an external magnetic field to increase the drug concentration in the region of interest (Magnetic-Drug-Targeting). We here present an analytical method (HPLC-UV), to detect pure or ferrofluid-bound mitoxantrone in a complex matrix even in trace amounts in order to perform biodistribution studies. Mitoxantrone could be extracted in high yields from different tissues. Recovery of mitoxantrone in liver tissue (5000 ng/g) was 76 ± 2%. The limit of quantification of mitoxantrone standard was 10 ng/mL ±12%. Validation criteria such as linearity, precision, and stability were evaluated in ranges achieving the FDA requirements. As shown for pilot samples, biodistribution studies can easily be performed after application of pure or ferrofluid-bound mitoxantrone.
This paper references
10.1002/BMC.1130080110
Direct determination of mitoxantrone in plasma by high performance liquid chromatography using an automatic precolumn-switching system as sample clean-up procedure.
J. Catalin (1994)
Guidance for Industry Bioanalytical Method Validation
(2001)
10.1016/S0021-9673(01)83574-3
High-performance liquid chromatographic determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorptive losses on glass during sample preparation.
K. T. Lin (1989)
10.1016/0378-4347(96)00023-0
Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography.
K. Rentsch (1996)
10.1016/J.JCHROMB.2004.03.044
Determination of isoflavones in soybean food and human urine using liquid chromatography with electrochemical detection.
B. Klejdus (2004)
Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.
M. E. Fox (1990)
10.1097/00007691-199308000-00011
A Sensitive and Simple High‐Performance Liquid Chromatographic Method for the Determination of Mitoxantrone in Plasma
L. Slørdal (1993)
10.1007/BF02497308
Determination of maltodextrins in enteral formulations by three different chromatographic methods
F. J. Moreno (1999)
10.1166/JNN.2006.464
Medical applications of magnetic nanoparticles.
C. Alexiou (2006)
10.2165/00003495-199141030-00007
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
D. Faulds (1991)
10.1016/J.IJPHARM.2005.09.037
Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. I: Formulation and in vitro characterization.
B. Lu (2006)
10.1016/0731-7085(94)00049-2
Improved LC assay for the determination of mitozantrone in plasma: analytical considerations.
M. J. Priston (1994)
10.1073/PNAS.81.23.7368
Condensation of nucleic acids by intercalating aromatic cations.
J. Kapuściński (1984)
Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting.
C. Alexiou (2007)
Guidance for Industry Bioanalytical Method Validation
FDA (2001)
10.2165/00003495-198734010-00003
Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.
A. Ward (1987)
Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.
J. Fidler (1986)
Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.
J. Fidler (1986)
10.1016/J.IJPHARM.2005.09.038
Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. II: Tissue distribution and pharmacodynamics.
B. Lu (2006)
Locoregional cancer treatment with magnetic drug targeting.
C. Alexiou (2000)
10.1088/0953-8984/18/38/S24
Drug loaded magnetic nanoparticles for cancer therapy
R. Jurgons (2006)
10.1166/JNN.2006.477
Quantification of magnetic nanoparticles by magnetorelaxometry and comparison to histology after magnetic drug targeting.
F. Wiekhorst (2006)
Polymer- und liposomstabilisierte Ferrofluide und ihre Funktionalisierung
M. Hodenius (2002)
10.1016/S0021-9673(02)01536-4
Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization.
G. A. Shabir (2003)
Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
L. Hollingshead (1991)
10.1016/S0168-3659(98)00098-4
Evaluation of mitoxantrone-loaded albumin microspheres following intraperitoneal administration to rats.
C. Luftensteiner (1999)
10.1016/J.JMMM.2006.10.1205
In vitro investigation of the behaviour of magnetic particles by a circulating artery model
C. Seliger (2007)
10.1016/J.JCHROMB.2003.10.034
Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation.
J. L. Johnson (2004)
Leitlinie zur Methodenvalidierung
J. Wellmitz (2005)



This paper is referenced by
10.1016/j.maturitas.2012.01.019
Magnetic nanovectors for drug delivery.
J. Klostergaard (2012)
10.2217/nnm.11.183
Magnetically vectored platforms for the targeted delivery of therapeutics to tumors: history and current status.
C. Seeney (2012)
10.2174/1874764711306010007
Design and Application of Magnetic-based Theranostic Nanoparticle Systems.
Aniket S Wadajkar (2013)
10.1016/J.SNB.2017.08.023
An Electrochemical Sensor Based on a Molecularly Imprinted Polymer for Determination of Anticancer Drug Mitoxantrone
Yan-rui Liu (2018)
10.1016/j.ejpb.2016.01.017
Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting.
J. Zaloga (2016)
10.1097/RLI.0b013e3182a7e1b7
Seven-Tesla Magnetic Resonance Imaging Accurately Quantifies Intratumoral Uptake of Therapeutic Nanoparticles in the McA Rat Model of Hepatocellular Carcinoma: Preclinical Study in a Rodent Model
P. Tyler (2014)
10.1016/J.JMMM.2014.08.041
Magnetic microgels for drug targeting applications: Physical–chemical properties and cytotoxicity evaluation
R. Turcu (2015)
10.1142/9789814520652_0016
Magnetic Nanoparticles for Drug Delivery
Rainer Dr. Tietze (2014)
10.1016/B978-0-12-385089-8.00005-4
Targeted Drug Delivery
Zoraida P. Aguilar (2013)
10.3109/1061186X.2012.750325
Specific targeting of cancer cells by multifunctional mitoxantrone-conjugated magnetic nanoparticles
Mostafa Heidari Majd (2013)
10.1016/j.nano.2012.05.010
Magnetic nanovectors for drug delivery.
J. Klostergaard (2012)
10.1016/j.colsurfb.2017.09.057
Studies on the adsorption and desorption of mitoxantrone to lauric acid/albumin coated iron oxide nanoparticles.
J. Zaloga (2018)
10.1016/J.JMMM.2010.11.059
Cancer therapy with drug loaded magnetic nanoparticles—magnetic drug targeting
C. Alexiou (2011)
10.1016/B978-0-12-385089-8.00009-1
Chapter 9 – Conclusions
Zoraida P. Aguilar (2013)
10.2147/IJN.S68539
Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility
J. Zaloga (2014)
10.1007/978-981-13-8954-2_3
Application of Nanoparticles in Dentistry: Current Trends
S. Priyadarsini (2020)
10.3390/ijms14047341
Magnetic Drug Targeting Reduces the Chemotherapeutic Burden on Circulating Leukocytes
C. Janko (2013)
10.2217/nnm.12.10
Nanoparticles for cancer therapy using magnetic forces.
R. Tietze (2012)
10.1515/bmt-2015-0049
Magnetic nanoparticles for magnetic drug targeting
S. Lyer (2015)
10.1515/bmt-2015-0055
Magnetorelaxometry procedures for quantitative imaging and characterization of magnetic nanoparticles in biomedical applications
M. Liebl (2015)
10.1007/s00106-012-2562-6
[Nanomedicine. Innovative applications in medicine].
C. Alexiou (2013)
10.2217/nnm.15.159
Nanomedical innovation: the SEON-concept for an improved cancer therapy with magnetic nanoparticles.
S. Lyer (2015)
10.1016/j.nano.2013.05.001
Efficient drug-delivery using magnetic nanoparticles--biodistribution and therapeutic effects in tumour bearing rabbits.
R. Tietze (2013)
Magnetic-based theranostic nanoparticles for prostate cancer management
Aniket S Wadajkar (2012)
10.1080/10408347.2018.1487776
Chromatographic Methods for Determination of Drugs Used in Prostate Cancer in Biological and Pharmacological Samples
C. Saka (2019)
Semantic Scholar Logo Some data provided by SemanticScholar